Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Monte Rosa Therapeutics presented new preclinical data regarding its MRT-8102 program at the ACR Convergence 2026 conference.
Stocks · News reference
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics announced that its management team will participate in several upcoming investor conferences throughout November and December 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026
Wells Fargo Maintains Buy Rating on Monte Rosa Therapeutics, Lowers Price Target
Wells Fargo analyst Derek Archila has maintained a 'Buy' rating on Monte Rosa Therapeutics while adjusting the price target from $29 to $25.
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25
Monte Rosa Therapeutics Grants Inducement Equity Awards to New Employees
Monte Rosa Therapeutics announced the grant of inducement equity awards to four newly hired non-executive employees.
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics reported its third-quarter 2026 financial results, highlighting clinical progress for its molecular glue degrader pipeline and a strong cash position.